Skip to content

Restricted Cash at other companies

ALN
Alnylam PharmaceuticalsALNY
$1.64M-36.8%
Septerna, Inc. logo
Septerna, Inc.SEPN
$905K0.0%
Regenxbio logo
RegenxbioRGNX
$2.03M0.0%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
$6.88M-13.3%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$57K
Ethos Technologies, Inc.
 logo
Ethos Technologies, Inc. LIFE
$1.81M-25.8%

Other financials

Income statement

See full
Operating income-$27.3M-49.2%
Net income-$25.2M-58.7%
EPS (diluted)-$1.34-44.1%

Balance sheet

See full
Cash & equivalents$236.9M-22.8%
Total debt$4.9M+86.1%
Total equity$230.4M-23.5%
Total assets$246.6M-21.7%

Cash flow

See full
Operating cash flow-$18.4M-40.7%
CapEx$19.0K-29.6%
Free cash flow-$18.4M-40.6%

Valuation

See full
Market cap$585.51M+58.3%
Enterprise value$353.51M+438%

Returns & leverage

See full
Return on equity-31.4%
Debt / equity0.0×
Current ratio18.5×-4.4×

Where this comes from

Reported directly by Tectonic Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashCurrent.

The official record: Tectonic Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tectonic Therapeutics's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tectonic Therapeutics's restricted cash?
Tectonic Therapeutics (TECX) reported restricted cash of $0 in Q1 2026.
How has Tectonic Therapeutics's restricted cash changed year-over-year?
Tectonic Therapeutics's restricted cash decreased by 100.0% year-over-year, from $587K to $0.
What is the long-term trend for Tectonic Therapeutics's restricted cash?
Over 5 years (2020 to 2025), Tectonic Therapeutics's restricted cash has grown at a 3.6% compound annual growth rate (CAGR), from $492K to $587K.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.